Recent News for DRRX - DURECT Corporation

Date Title
Mar 14 Durect (DRRX) Investor Presentation - Slideshow
Mar 9 DURECT Corporation Announces Publication of DUR-928's Mechanism of Action
Mar 5 DURECT Corporation (DRRX) CEO Jim Brown on Q4 2020 Results - Earnings Call Transcript
Mar 4 Durect: Q4 Earnings Insights
Mar 4 Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
Mar 4 Durect EPS misses by $0.02, misses on revenue
Mar 4 Earnings Scheduled For March 4, 2021
Mar 3 DURECT Corporation to Participate in Three Investor Conferences in March 2021
Feb 24 Durect: Positive Data In Alcoholic Hepatitis, But Catalysts Too Far Away
Feb 4 DURECT prices ~$43M stock offering
Feb 4 DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock
Feb 3 DURECT under pressure on launching stock offering
Feb 3 DURECT Corporation Announces Proposed Offering of Common Stock
Feb 2 Durect stock soars 34% after it gets FDA approval for surgical pain treatment
Feb 2 DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression
Feb 2 DURECT surges after FDA approval for Posimir
Jan 25 Dosing underway in DURECT's DUR-928 mid-stage study in alcoholic hepatitis
Jan 25 DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis
Jan 5 DURECT Corporation Appoints Two New Board Members
Jan 4 DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million
Dec 21 DURECT Corporation to Participate in Investor Conferences in January 2021
Dec 16 Durect's DUR-928 fast track'd for alcoholic hepatitis in the U.S.
Dec 16 DURECT Corporation Announces DUR-928 Granted FDA Fast Track Designation for Treatment of Alcoholic Hepatitis
Dec 9 Is DRRX A Good Stock To Buy Now?
Dec 7 DURECT to sell its LACTEL absorbable polymer product line to Evonik for $15M
Back to the Main DRRX Page...